[SCHEDULE 13G/A] CytomX Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Tang Capital Management and related entities report ownership of 11,065,662 shares of CytomX Therapeutics common stock, representing 7.0% of the outstanding class. The filing shows no sole voting or dispositive power; all reported shares are held with shared voting and dispositive power. The percentages are calculated using 157,544,369 shares outstanding per the issuer prospectus. The filers certify the stake is not held to influence control of the company.

Positive

• Material passive stake disclosed: Reporting persons hold 11,065,662 shares (7.0%) of CTMX, providing transparency to the market.
• Shared voting and dispositive power disclosed: Filing clearly states shared voting and shared dispositive power over the shares.
• Certification of non-control intent: Filers certify the shares are not held to change or influence control, clarifying intent.

Negative

• None.

Insights

Securities Analyst

TL;DR: Tang Capital group holds a disclosed 7.0% passive stake (11.07M shares) in CytomX, reported with shared voting/dispositive power.

The Schedule 13G/A reports that Tang Capital Management, Kevin Tang, Tang Capital Partners, LP and Tang Capital Partners International, LP collectively beneficially own 11,065,662 shares, equal to 7.0% of CytomX common stock based on 157,544,369 shares outstanding. The filing indicates no sole voting or dispositive power and contains a certification that the holdings are not intended to change or influence control. For investors, this is a transparency filing showing a material passive ownership position without control intent.

Corporate Governance Expert

TL;DR: Disclosure clarifies group ownership structure and shared authority but asserts no intent to influence company control.

The Schedule 13G/A details the relationships among the reporting persons and discloses shared voting and disposition authority over the reported shares. The explicit statement that the holdings are not for the purpose of changing control is important for governance signaling. The filing identifies the precise addresses, citizenships, and roles of the reporting entities and individual signatory, supporting regulatory compliance and shareholder transparency.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)

CytomX Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

23284F105

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 23284F105

1

Names of Reporting Persons

TANG CAPITAL MANAGEMENT, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 11,065,662.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 11,065,662.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,065,662.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.0 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Tang Capital Management, LLC ("TCM") shares voting and dispositive power over such shares with Tang Capital Partners, LP ("TCP"), Tang Capital Partners International, LP ("TCPI") and Kevin Tang. The percentages used herein are based on 157,544,369 shares of Common Stock outstanding as of May 9, 2025, as set forth in the Prospectus Report filed on Form 424B5 that was filed with the Securities and Exchange Commission on May 12, 2025.

SCHEDULE 13G

CUSIP No. 23284F105

1

Names of Reporting Persons

KEVIN TANG

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 11,065,662.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 11,065,662.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,065,662.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.0 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Kevin Tang shares voting and dispositive power over such shares with TCP, TCPI and TCM.

SCHEDULE 13G

CUSIP No. 23284F105

1

Names of Reporting Persons

TANG CAPITAL PARTNERS, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,409,997.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,409,997.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,409,997.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.7 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: TCP shares voting and dispositive power over such shares with TCM and Kevin Tang.

SCHEDULE 13G

CUSIP No. 23284F105

1

Names of Reporting Persons

TANG CAPITAL PARTNERS INTERNATIONAL, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,655,665.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,655,665.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,655,665.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.3 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: TCPI shares voting and dispositive power over such shares with TCM and Kevin Tang.

SCHEDULE 13G

CUSIP No. 23284F105

1

Names of Reporting Persons

TANG CAPITAL PARTNERS III, INC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEVADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP No. 23284F105

1

Names of Reporting Persons

TANG CAPITAL PARTNERS IV, INC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEVADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CytomX Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, 94080
Item 2.
(a)	Name of person filing: This Statement on Schedule 13G (this "Statement") is filed by TCM, the general partner of TCP and TCPI; Kevin Tang, the manager of TCM and Chief Executive Officer of Tang Capital Partners III, Inc. ("TCP III") and Tang Capital Partners IV, Inc. ("TCP IV"); TCP; TCPI; TCP III; and TCP IV.
(b)	Address or principal business office or, if none, residence: The address of TCM, Kevin Tang, TCP and TCPI is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of TCP III and TCP IV is 400 S. 4th Street, 3rd Floor, Las Vegas, NV 89101.
(c)	Citizenship: TCM is a Delaware limited liability company. Mr. Tang is a United States citizen. TCP and TCPI are Delaware limited partnerships. TCP III and TCP IV are Nevada corporations that are indirectly wholly owned by TCP.
(d)	Title of class of securities: Common Stock, par value $0.00001 per share
(e)	CUSIP No.: 23284F105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 11,065,662
(b)	Percent of class: 7.0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0 shares
	(ii) Shared power to vote or to direct the vote: 11,065,662 shares
	(iii) Sole power to dispose or to direct the disposition of: 0 shares
	(iv) Shared power to dispose or to direct the disposition of: 11,065,662 shares
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

TANG CAPITAL MANAGEMENT, LLC

Signature:	/s/ Kevin Tang
Name/Title:	Manager
Date:	08/14/2025

KEVIN TANG

Signature:	/s/ Kevin Tang
Name/Title:	Self
Date:	08/14/2025

TANG CAPITAL PARTNERS, LP

Signature:	/s/ Kevin Tang
Name/Title:	Manager, Tang Capital Management, LLC, General Partner
Date:	08/14/2025

TANG CAPITAL PARTNERS INTERNATIONAL, LP

Signature:	/s/ Kevin Tang
Name/Title:	Manager, Tang Capital Management, LLC, General Partner
Date:	08/14/2025

TANG CAPITAL PARTNERS III, INC

Signature:	/s/ Kevin Tang
Name/Title:	Chief Executive Officer
Date:	08/14/2025

TANG CAPITAL PARTNERS IV, INC

Signature:	/s/ Kevin Tang
Name/Title:	Chief Executive Officer
Date:	08/14/2025

FAQ

How many CytomX (CTMX) shares does Tang Capital report owning?

The filing reports 11,065,662 shares, representing 7.0% of CytomX common stock based on 157,544,369 shares outstanding.

Does Tang Capital have sole voting or dispositive power over the CTMX shares?

No. The filing reports 0 shares with sole voting or sole dispositive power and 11,065,662 shares with shared voting and shared dispositive power.

When was this Schedule 13G/A signed and who signed it?

The signatures on the filing are dated 08/14/2025 and signed by /s/ Kevin Tang in capacities including Manager and Chief Executive Officer.

What percentage of CytomX does the reported stake represent?

The reported stake represents 7.0% of the outstanding common stock, calculated using 157,544,369 shares outstanding.

Does the filing indicate the stake is intended to influence control of CytomX?

No. Item 10 contains a certification that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.